IMPACTfolio LLC Takes $220,000 Position in Gilead Sciences, Inc. (NASDAQ:GILD)

IMPACTfolio LLC bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,379 shares of the biopharmaceutical company’s stock, valued at approximately $220,000.

Several other institutional investors also recently bought and sold shares of the stock. nVerses Capital LLC purchased a new position in Gilead Sciences in the third quarter valued at $25,000. Valued Wealth Advisors LLC increased its stake in shares of Gilead Sciences by 101.9% in the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 161 shares in the last quarter. Cedar Wealth Management LLC raised its holdings in Gilead Sciences by 51.6% in the 2nd quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 160 shares during the period. Strategic Investment Solutions Inc. IL purchased a new position in Gilead Sciences during the second quarter worth approximately $33,000. Finally, Quarry LP acquired a new stake in Gilead Sciences in the second quarter valued at approximately $43,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 248,645 shares of the business’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the completion of the transaction, the chief financial officer now directly owns 138,919 shares of the company’s stock, valued at $12,886,126.44. The trade was a 64.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Merdad Parsey sold 164,211 shares of the stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the completion of the sale, the insider now directly owns 80,801 shares in the company, valued at $7,427,227.92. This represents a 67.02 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 453,734 shares of company stock worth $41,902,086 over the last three months. Company insiders own 0.29% of the company’s stock.

Gilead Sciences Trading Down 0.4 %

Shares of GILD traded down $0.34 during trading on Thursday, reaching $92.03. 1,954,585 shares of the company traded hands, compared to its average volume of 7,043,598. The stock has a 50-day simple moving average of $91.70 and a 200-day simple moving average of $82.15. The stock has a market cap of $114.69 billion, a PE ratio of 1,022.56, a price-to-earnings-growth ratio of 2.38 and a beta of 0.18. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $98.90. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. During the same quarter in the previous year, the company earned $2.29 earnings per share. The firm’s quarterly revenue was up 7.0% compared to the same quarter last year. On average, analysts anticipate that Gilead Sciences, Inc. will post 4.35 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were given a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 3.35%. The ex-dividend date was Friday, December 13th. Gilead Sciences’s dividend payout ratio is currently 3,422.22%.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on GILD shares. Citigroup initiated coverage on Gilead Sciences in a research report on Thursday, November 14th. They set a “buy” rating and a $125.00 target price on the stock. BMO Capital Markets lifted their target price on shares of Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Royal Bank of Canada restated a “sector perform” rating and set a $84.00 price target on shares of Gilead Sciences in a research report on Wednesday, December 11th. Wells Fargo & Company lifted their price objective on Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Finally, Bank of America restated a “buy” rating and issued a $109.00 target price on shares of Gilead Sciences in a research report on Tuesday, December 10th. Twelve equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and four have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average price target of $96.43.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.